Core Viewpoint - Weigao Blood Products announced that its stock price experienced a significant fluctuation, with a cumulative increase of over 20% in the closing price over two consecutive trading days [1] Group 1: Stock Performance - The stock price fluctuation is classified as an abnormal trading situation according to the Shanghai Stock Exchange trading rules [1] - The company confirmed that its production and operations are normal and no significant media reports or market rumors have been found that could impact the stock price [1] Group 2: Major Asset Restructuring - The company is advancing a major asset restructuring plan to acquire 100% equity of Weigao Purui through a share issuance [1] - This restructuring plan has been approved by the company's board of directors but still requires approval from the shareholders' meeting, indicating some uncertainty regarding the matter [1] Group 3: Investor Advisory - The company advises investors to be cautious of secondary market trading risks and to make rational investment decisions [1]
威高血净：股票交易异常波动